TOKYO & HONG KONG--(BUSINESS WIRE)--Solasia Pharma K.K. (Headquarters: Tokyo, Japan, President: Yoshihiro Arai, hereinafter “Solasia”) and Lee’s Pharmaceutical Holdings Limited (hereinafter “Lee’s Pharma”)(SEHK stock code: 0950) jointly announced today that Solasia and Lee’s Pharma have entered into an exclusive agreement for the commercialization and promotion of episil® in the People’s Republic of China (the “PRC”), Hong Kong and Macau, excluding Taiwan and the Retained Territory (defined hereafter). Solasia will retain rights to commercialize and promote episil® in three major cities (Beijing, Shanghai and Guangzhou; the “Retained Territory”) in the PRC.
Solasia has obtained an exclusive license to develop and commercialize episil® in Japan and the PRC from Camurus AB (“Camurus”) (STO: CAMX) in 2015. In 2016, Solasia filed for New Medical Device Application for episil® in Japan and the PRC.
episil® oral liquid represents a unique and innovative concept for local treatment of pain associated with oral mucositis (OM). Having been developed using the award-winning* Camurus proprietary technology FluidCrystal®, episil® is administered as lipid-based liquid that spreads on the intraoral mucosal surfaces and transforms to strongly bioadhesive film, which physically protects the sensitized and sore mucosa of the oral cavity. episil® has clinically demonstrated to rapidly (within minutes) and effectively reduce oral pain for up to 8 hours. episil® oral liquid is the only product for OM that is supplied as a ready-to-use, pocket-sized device helping patients maintain their quality of life while undergoing cancer therapy. episil® was first launched in Europe in 2009 and is today commercially available in a number of countries, including the U.S. where it was launched by key global pharmaceutical players. episil® oral liquid is a medical device class 1 in Europe and a 510(k) registered medical device in the U.S.
*FluidCrystal® was awarded the “Best innovation in formulation” prize at the CPhI Worldwide in 2013
“In addition to the existing partnership we already have with Lee’s Pharma, we are extremely pleased to further strengthening our partnership with the addition of episil®. As we prepare for commercialization in the PRC, we believe our extensive partnership would enable us to cover a large part of mainland China to support cancer patients suffering from OM,” said Mr. Yoshihiro Arai, President & Representative Director. “Oral mucositis is a difficult symptom to control for patients receiving chemotherapy and radiotherapy. episil® with its uniqueness of ready-to-use, pocket sized device, we hope to change the treatment landscape in the field of OM.”
“We respect and value Solasia’s commitment to oncology and this collaboration will further contribute to enhance Lee’s Pharma’s capabilities in this therapeutic area,” said Dr. Li Xiaoyi, Chief Executive Officer and Executive Director of Lee's Pharma. “Lee’s Pharma will work robustly with Solasia in close cooperation to accelerate commercialization of episil® and bring a new therapeutic option to cancer patients in the PRC.”
Solasia was formed in November 2006 to address unmet needs for important new Western oncology therapies and supportive care products throughout Asia. The company’s mission is to expedite patient access to unique oncology therapies through aggressive development and specialized commercialization throughout Japan, China and other Asian countries. To date, Solasia has raised approximately $80 million in venture financing. Additional information is available at http://www.solasia.co.jp/en/
About Lee’s Pharma:
Lee's Pharma is a research-based biopharmaceutical company listed in Hong Kong with more than 20 years of operation in China's pharmaceutical industry. It is fully integrated with a strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnerships with more than 20 international companies and currently has 14 products in the market place. Lee's Pharma focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. The company’s development program has produced 30 product candidates resulting from both internal R&D efforts and collaborations with U.S., European and Japanese companies, including promising compounds to treat liver cancer and pulmonary hypertension. The mission of Lee's Pharma is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information is available at http://www.leespharm.com.
Safe Harbor Statement
The performance and the results of operation of Lee’s Pharma during the past years are historical in nature and past performance can be no guarantee of future results of the Lee’s Pharma. This news release may contain forward-looking statements and opinions that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Neither Lee’s Pharma nor the Directors, employees or agents of Lee’s Pharma assume (a) any obligation to correct or update the forward-looking statements or opinions contained in this news release; and (b) any liability in the event that any of the forward-looking statements or opinions does not materialise or turns out to be incorrect.